1 / 4

Clinical Protocols for Hepatitis C Patients: Anti-Polymerase Trials and Non-Responders

This document outlines various protocols for treating naive and non-responder Hepatitis C (HCV) patients using Pegasys and Copegus, including the NV19865 trial for naive patients and the SYREN protocol for non-responders. The NV19865 protocol involves randomization into groups receiving treatment for either 24 or 48 weeks, while the SYREN protocol administers a higher dosage for 48 weeks. Additionally, the NRFI protocol addresses non-responders receiving pegIFN with ribavirin over 36 months. For further inquiries, please contact Juliette Foucher at chu-bordeaux.

kaden
Télécharger la présentation

Clinical Protocols for Hepatitis C Patients: Anti-Polymerase Trials and Non-Responders

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Les protocoles... NV19865 : 1er essai d’une anti-polymérase Patients VHC Naifs Pégasys + copégus + antipolymérase Randomisation 6/1 24 ou 48 semaines Génotype 1 PBH

  2. Les protocoles… SYREN : non répondeurs Patients VHC non répondeurs pégasys + copégus Pégasys 360 µg Copégus 1000-1600 mg 48 semaines pas de PBH

  3. Les protocoles… NRFI Patients VHC non répondeurs pegIFN suspensif +/- ribavirine Pendant 36 mois PBH

  4. Pour tout renseignement contacter Juliette Foucher juliette.foucher@chu-bordeaux.fr

More Related